Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment

Yu Shan Chang, Ying Tin Chen, Tso Ting Lai, Hung Chieh Chou, Chien Yi Chen, Wu Shiun Hsieh, Chung May Yang, Po Ting Yeh, Po Nien Tsao

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

This single-centered, retrospective cohort study investigated the timing of involution of retinopathy of prematurity (ROP) and retinal vascularization to zone III after intravitreal bevacizumab (IVB) treatment and its possible impacts on postnatal growth and neurodevelopment. Premature infants with birth weight .1500 g, born between 2008 to 2014 and diagnosed with ROP were enrolled. All patients with type 1 ROP underwent IVB as 1st line treatment and were recruited as the study group; those with any stage of ROP except type 1 ROP without treatment served as controls. Neurodevelopmental outcomes were assessed using the Bayley Score of Infant Development (BSID) editions II or III. The study group included 35 eyes from 18 patients; the control group included 86 patients. Twenty-three eyes (65.7%) exhibited ROP regression after a single dose of IVB. The majority of plus sign and extraretinal neovascularization regressed within two weeks. The length of time for retinal vascularization to reach zone III was significantly longer in the treatment group compared with the control (mean post-menstruation age 54.5 vs. 47.0 weeks, p<0.001). Longterm follow-up showed no significant differences in body weight and neurodevelopment between the study and control groups up to the 2-year corrected age.

Original languageEnglish
Article numbere0223972
JournalPloS one
Volume14
Issue number10
DOIs
Publication statusPublished - 2019 Oct 1

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment'. Together they form a unique fingerprint.

Cite this